CTOs on the Move

Progenity

www.progenity.com

 
Progenity, Inc. is a biotechnology company innovating in the fields of women`s health, gastrointestinal health, and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity`s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.progenity.com
  • 4330 La Jolla Village Drive
    San Diego, CA USA 92122
  • Phone: 855.293.2639

Executives

Name Title Contact Details
Paul Shabram
Senior Vice President of Technical Operations Profile
Launa Saunders
Director of IT, Sales and Marketing Platforms Profile
Troy Seelye
Senior Vice President and Chief Information Officer Profile

Funding

Progenity raised $125M on 11/07/2017
Progenity raised $40M on 06/10/2021

Similar Companies

Threshold Enterprises

Threshold Enterprises is a wholesale distributor of dietary supplements and health care products to the natural foods industry and health care professionals. We don't sell directly to consumers. If you want to open an account, or are a current customer

Symic Biomedical

Symic is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. While it is clear that cells play an important role in tissue inflammation and regeneration, it is also known that the extracellular matrix (ECM) plays an equally critical role in maintaining healthy tissue. The ECM is the non-cellular component of the body’s tissues, and proteoglycans are important structural and functional macromolecules native to the ECM that are known to protect against tissue degradation and promote healing during illness or injury. Recognizing the importance of proteoglycans in many acute and chronic disease states, Symic developed a library of proprietary, ECM-specific compounds that mimic the protective effect of natural proteoglycans. For controlled injuries (e.g. incisions, balloon angioplasty), Symic’s ECM-specific compounds allow for local application, enhancing their ability to attenuate inflammation and reduce scarring only at the site of injury. In disease states known for chronic inflammation involving the ECM (e.g. cartilage in osteoarthritis), Symic’s technology can disrupt the cycle of degradation-inflammation by directly targeting and protecting the injured ECM. The ECM plays a critical role in many acute and chronic disease states, many of which have limited or no effective therapeutic options. Symic plans to advance its compounds in a variety of therapeutic areas with unmet clinical needs.

ADMEDES SCHUESSLER GmbH

ADMEDES SCHUESSLER GmbH is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LTZ Therapeutics

LTZ Therapeutics is an immunotherapy-focused biotech company to develop novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need.

Isis Pharmaceuticals Inc

Isis Pharmaceuticals Inc is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.